Results of adjuvant BCG immunotherapy in malignant melanoma.
98 stage I melanoma patients and 16 stage II melanoma patients were included in this BCG immunotherapy trial. The postoperative treatment was performed by a high dose of BCG (Jena strain) administered by scarification with an intensive schedule. Compared to a similar historical control group treated by surgery alone (69 cases), the stage I melanoma patients showed a significantly improved recurrence rate and survival rate. In stage II melanoma patients we cannot prove any therapeutical effect of BCG therapy.